960 x 350_41

In Vitro Metabolism

The ADME assay development pipeline includes in vitro ADME assays that are necessary once a lead candidate has been selected. The safety profile of a drug candidate will depend partly on its interactions with other drugs, especially those that may be administered concomitantly in standard-of-care treatment. Assessing the risks of possible drug-interactions using validated bioanalytical methods is thus an essential early step in the candidate development process. Q2 Solutions offers a suite of in vitro assays to support drug-drug interaction testing, including cytochrome P450 (CYP) enzyme inhibition (IC50), time-dependent CYP inhibition, induction of CYP enzymes, and CYP reaction phenotyping. All in vitro metabolism assay results are presented in fully QC-reviewed, regulatory-style reports to support filing of IND applications.

Assessing Drug-Drug Interaction Risks

Drug-drug interaction testing provides a definitive assessment of these risks and should be performed early after selection of a lead candidate

Learn more
Q2-Header_1280x350_2

Related Thought Leaders Insights


Sense and Sensitivity – or the Pursuit of Actionable Insight in the Age of Single-Cell Biology

Speaker -  Oswaldo A Lozoya, PhD, Genomics Staff Scientist - TSAIL, Q2 Solutions   As part of the Machine Learning and Single Cell Genomics in Public Health session, Oswaldo presents insights,...

Renal Function and Race in Clinical Trials

The glomerular filtration rate (GFR) is a critical indicator of kidney function, and its value may be measured using a simple blood test for creatinine. Historically, studies have shown that people...

NASH and Liver Disease Capabilities

As a leading laboratory services organization for trials across the globe, we integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize your...